MA30050B1 - Preparation comprenant des composes complexes de fer (iii) et une ou plusieurs susbtances a activite redox . - Google Patents

Preparation comprenant des composes complexes de fer (iii) et une ou plusieurs susbtances a activite redox .

Info

Publication number
MA30050B1
MA30050B1 MA31032A MA31032A MA30050B1 MA 30050 B1 MA30050 B1 MA 30050B1 MA 31032 A MA31032 A MA 31032A MA 31032 A MA31032 A MA 31032A MA 30050 B1 MA30050 B1 MA 30050B1
Authority
MA
Morocco
Prior art keywords
iron
iii
preparation
complex compounds
hydrogenated
Prior art date
Application number
MA31032A
Other languages
English (en)
Inventor
Priska Ziegler
Peter Geisser
Original Assignee
Vifor Internat Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor Internat Ag filed Critical Vifor Internat Ag
Publication of MA30050B1 publication Critical patent/MA30050B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Une préparation est révélée qui comprend un ou plusieurs composés complexes de fer(III) qui présentent un potentiel redox à pH de 7 compris entre -324 mV à -750 Mv par rapport à une électrode normale à hydrogène (ENH), et une ou plusieurs substances à activité redox, dans laquelle les hydrates de carbone sont choisis parmi le groupe consistant en dextrans et dextrans hydrogénés, dextrines, dextrines oxydées ou hydrogénées, ainsi que le pullulan, des oligomères de ceux-ci et/ou les pullulans hydrogénés, et dans laquelle la/les substance(s) à activité redox est/sont choisie(s) parmi le groupe consistant en acide ascor-bique; vitamine E; cystéine; phénols/polyphénols physiologiquement acceptables choisis parmi le groupe consistant en quercétine, rutine, flavones, flavonoïdes, hydroquinones; et le glutathion, et en particulier l'acide ascorbique.
MA31032A 2005-11-24 2008-06-13 Preparation comprenant des composes complexes de fer (iii) et une ou plusieurs susbtances a activite redox . MA30050B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05111229A EP1790356A1 (fr) 2005-11-24 2005-11-24 Préparation contenant des complexes de fer(III) et des composés rédoxs

Publications (1)

Publication Number Publication Date
MA30050B1 true MA30050B1 (fr) 2008-12-01

Family

ID=36617266

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31032A MA30050B1 (fr) 2005-11-24 2008-06-13 Preparation comprenant des composes complexes de fer (iii) et une ou plusieurs susbtances a activite redox .

Country Status (17)

Country Link
US (2) US20080269167A1 (fr)
EP (2) EP1790356A1 (fr)
JP (1) JP2009517359A (fr)
KR (1) KR101153461B1 (fr)
CN (1) CN101312746B (fr)
AU (1) AU2006316717B2 (fr)
BR (1) BRPI0618875A2 (fr)
CA (1) CA2626062C (fr)
IL (1) IL190878A0 (fr)
MA (1) MA30050B1 (fr)
MY (1) MY151821A (fr)
NO (1) NO20082384L (fr)
NZ (1) NZ567844A (fr)
RU (1) RU2394597C2 (fr)
TN (1) TNSN08216A1 (fr)
WO (1) WO2007060038A2 (fr)
ZA (1) ZA200804505B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US8709709B2 (en) 2007-05-18 2014-04-29 Luoxis Diagnostics, Inc. Measurement and uses of oxidative status
JP5330381B2 (ja) 2007-05-18 2013-10-30 インスティチュート フォー モレキュラー メディスン インコーポレイテッド 酸化還元電位（ｏｒｐ）を測定及び使用する方法
US8473518B1 (en) 2008-07-03 2013-06-25 Salesforce.Com, Inc. Techniques for processing group membership data in a multi-tenant database system
RU2455999C2 (ru) * 2010-09-29 2012-07-20 Общество с ограниченной ответственностью "БиоФармГарант" Препарат для лечения и профилактики железодефицитных состояний у животных
WO2012104204A1 (fr) 2011-01-31 2012-08-09 Vifor (International) Ag Composés à base d'un complexe de fer-hydrate de carbone pour la thérapie intraveineuse du paludisme
AU2012223511B2 (en) 2011-02-28 2015-04-09 Caerus Biotechnologies Method and apparatus for measuring oxidation-reduction potential
KR20150013146A (ko) 2012-04-19 2015-02-04 로익스 다이어그노스틱스, 아이엔씨. 다층겔
US9308216B2 (en) * 2012-10-22 2016-04-12 Alps Pharmaceuticals Ind. Co., Ltd. Rutin-rich extract and method of making same
CA2847665A1 (fr) 2012-10-23 2014-04-23 Raphael Bar-Or Procedes et systemes pour mesurer et utiliser le potentiel d'oxydo-reduction d'un echantillon biologique
CN104887696B (zh) * 2014-03-04 2018-06-29 天津怀仁制药有限公司 右旋糖酐铁和维生素c的复方制剂
IT201700089258A1 (it) * 2017-08-02 2019-02-02 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di carenza di ferro
GR1009589B (el) * 2018-04-05 2019-09-11 Ιουλια Κλεωνος Τσετη Φαρμακευτικο σκευασμα για την αντιμετωπιση της αναιμιας, σε καταλληλο περιεκτη, που διατηρει στεγανα διαχωρισμενα μεταξυ τους τα δραστικα συστατικα: συμπλοκο του τρισθενους σιδηρου με ν-ακετυλο-l-ασπαρτικη καζεϊνη και πενταϋδρικο φυλλινικο ασβεστιο
GR1009597B (el) * 2018-04-16 2019-09-16 Ιουλια Κλεωνος Τσετη Φαρμακευτικο σκευασμα για την ενισχυση των επιπεδων σιδηρου στο αιμα, που περιεχει πολυμαλτοζικο σιδηρο (ιιι) και μια δραστικη ουσια επιλεγμενη απο πενταϋδρικο φυλλινικο ασβεστιο, βιταμινη c ή συνδυασμο των δυο, που ενισχυει την απορροφηση σιδηρου
CN112516793A (zh) * 2020-11-10 2021-03-19 东华理工大学 一种异VC钠还原Fe(III)EDTA的方法及应用其脱除废气中NO的方法
CN114539610B (zh) * 2022-03-15 2023-09-15 集美大学 一种从琼脂生产废液中回收制备抗菌剂的方法
KR102623739B1 (ko) * 2022-07-28 2024-01-11 주식회사 페라메드 시트르산과 철을 포함하는 착화합물 및 그를 포함하는 식품 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076798A (en) * 1961-02-23 1963-02-05 Hausmann Lab Ltd Process for preparing a ferric hydroxide polymaltose complex
JPS606619A (ja) * 1983-06-27 1985-01-14 Kyowa Chem Ind Co Ltd 鉄分欠乏症処置剤及びその製法
US4994283A (en) * 1987-07-02 1991-02-19 The Procter & Gamble Company Iron-calcium mineral supplements with enhanced bioavailability
US4992282A (en) * 1989-05-08 1991-02-12 The Procter & Gamble Company Stable nutritional vitamin and mineral supplemented beverage
JPH0367571A (ja) * 1989-08-07 1991-03-22 Kansai Paint Co Ltd 鉄分強化清涼飲料水
DE4421159C1 (de) * 1994-06-20 1995-08-24 Thomas Bruns Verwendung von Eisen(III)-oxid (Fe¶2¶O¶3¶) bei Immunschwäche
DE19734293A1 (de) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
WO2001000204A1 (fr) * 1999-06-30 2001-01-04 Ajay Gupta Methode et composition pharmaceutique pour l'administration parenterale de fer
DK1072198T3 (da) * 1999-07-28 2008-09-22 Swiss Caps Rechte & Lizenzen Præparat til anvendelse som medikament og/eller ernæringstilskud
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
EP1363951B1 (fr) * 2000-12-07 2006-10-25 AD "Zdravlje" Farmaceutsko - Hemijska Industrija, Centar Za Istrzivanje I Razvoj Complexe polynucleaire fe(iii) contenant des oligomeres de pullulane, methode de production, et preparations pharmaceutiques obtenues a partir du complexe
WO2003087164A1 (fr) * 2002-04-09 2003-10-23 Pharmacosmos Holding A/S Composes de dextrine de fer concus pour traiter une anemie ferriprive
DE10249552A1 (de) * 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US6960571B2 (en) * 2003-03-14 2005-11-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US20060116349A1 (en) * 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
AU2007205167B2 (en) * 2006-01-06 2013-06-13 Vifor (International) Ag Methods and compositions for administration of iron

Also Published As

Publication number Publication date
NO20082384L (no) 2008-05-26
CN101312746B (zh) 2012-12-12
BRPI0618875A2 (pt) 2011-09-13
IL190878A0 (en) 2008-11-03
KR101153461B1 (ko) 2012-07-09
CA2626062C (fr) 2015-02-03
WO2007060038A2 (fr) 2007-05-31
JP2009517359A (ja) 2009-04-30
NZ567844A (en) 2011-05-27
WO2007060038A3 (fr) 2008-05-08
AU2006316717A1 (en) 2007-05-31
EP1954314A2 (fr) 2008-08-13
ZA200804505B (en) 2009-02-25
EP1790356A1 (fr) 2007-05-30
MY151821A (en) 2014-07-14
US20080269167A1 (en) 2008-10-30
KR20080071566A (ko) 2008-08-04
RU2008125327A (ru) 2009-12-27
AU2006316717B2 (en) 2011-10-20
RU2394597C2 (ru) 2010-07-20
TNSN08216A1 (en) 2009-10-30
CA2626062A1 (fr) 2007-05-31
US20130157974A1 (en) 2013-06-20
CN101312746A (zh) 2008-11-26

Similar Documents

Publication Publication Date Title
MA30050B1 (fr) Preparation comprenant des composes complexes de fer (iii) et une ou plusieurs susbtances a activite redox .
Vial et al. Role of mitochondria in the mechanism (s) of action of metformin
Genova et al. The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron–sulfur cluster N2
JP2851289B2 (ja) グルタチオン誘導体の薬物治療的用途
Turrens et al. Ubisemiquinone is the electron donor for superoxide formation by complex III of heart mitochondria
Subathra et al. Emerging role of Centella asiatica in improving age-related neurological antioxidant status
Yamashita et al. Mechanism of oxidative DNA damage induced by quercetin in the presence of Cu (II)
Fernandez et al. Iron and copper chelation by flavonoids: an electrospray mass spectrometry study
US7740831B2 (en) Compositions for potentiating glutathione
Hodnick et al. Inhibition of mitochondrial respiration and cyanide-stimulated generation of reactive oxygen species by selected flavonoids
Koch et al. Oxidative stress and antioxidant defenses in ethanol-induced cell injury
Ye et al. Cytotoxic effects of Mn (III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate
HUP0302021A2 (hu) Szteroid tartalmú stabilizált vizes szuszpenziók parenterális használathoz
MA28038A1 (fr) Thienopyrazoles
Jacintho et al. Neurotransmission and neurotoxicity by nitric oxide, catecholamines, and glutamate: unifying themes of reactive oxygen species and electron transfer
Ye et al. Suppressive effects of active hexose correlated compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress
DK1161228T3 (da) Præparat omfattende isoquercetin og ascorbinsyre i en sustained release-form
Zimmer et al. Dose/response curves of lipoic acid R-and S-forms in the working rat heart during reoxygenation: superiority of the R-enantiomer in enhancement of aortic flow
Circu et al. Low glucose stress decreases cellular NADH and mitochondrial ATP in colonic epithelial cancer cells: Influence of mitochondrial substrates
TR199700858A2 (xx) Alzheimer hastal���n�n tedavisine y�nelik ispen�iyari bile�imler.
DE60117248D1 (de) Parenterale lösung enthaltend amiodaron
Sharma et al. Attenuation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine
CA2088994C (fr) Melange de glutathion et de composes d'anthocyanine a action therapeutique
Devi et al. Effect of citrate stabilized gold nanoparticle on the biochemical and histological alterations of liver in an experimental animal model
Ordoñez et al. Thiol oxidation coupled to DT-diaphorase-catalysed reduction of diaziquone. Reductive and oxidative pathways of diaziquone semiquinone modulated by glutathione and superoxide dismutase